In other words, be prepared to put in a lot of effort to convince your provider you really do need this medication
specifically examined patients with MASLD cirrhosis and type 2 diabetes, finding that GLP-1 receptor agonist initiation was linked to reduced risk of unfavorable liver outcomes including hepatic decompensation events and mortality from any cause (aHR: 0.78, 95%CI: 0.68-0.90) relative to non-users, suggesting potential benefits even in advanced liver disease populations [58]
The trial demonstrated a significant reduction of 25% in the primary composite outcome of cardiovascular death and first HFH (19.4% versus 24.7% [HR 0.75
Factors affecting real-world results include dosing adjustments for side effects, adherence challenges, and less intensive lifestyle support than in trials
In May 2026, Lilly reported that in a late-stage trial of adults with obesity or overweight and at least one weight-related comorbidity, the highest 12 mg dose of retatrutide produced 28.3% average weight loss over 80 weeks, and more than 45% of participants lost 30% or more of their body weight
What to Expect in Months 7-11 Essentially no side effects: Appetite suppression continues (desired effect), but GI symptoms gone Weight loss velocity slows: From 0.8kg/week (months 3-6) to 0.3-0.5kg/week Plateau around week 40-48: Weight stabilizes, no longer losing despite continued medication Total weight loss: Average 20-24% from baseline (matching or exceeding surgical outcomes) Focus shifts to maintenance: Accepting current weight, preventing regain Plateau frustration: Not a side effect but an emotional challenge 2 Final Strategies for Months 7-11 20
